Ocugen Inc
OCGN1.330USD
0.0000.00%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
415.39MCap. mercado
PérdidaP/E TTM
Más Datos de Ocugen Inc Compañía
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Información de Ocugen Inc
Símbolo de cotizaciónOCGN
Nombre de la empresaOcugen Inc
Fecha de salida a bolsaDec 03, 2014
Director ejecutivoMusunuri (Shankar)
Número de empleados95
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 03
Dirección11 Great Valley Parkway
CiudadMALVERN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19355
Teléfono14843284701
Sitio Webhttps://ocugen.com/
Símbolo de cotizaciónOCGN
Fecha de salida a bolsaDec 03, 2014
Director ejecutivoMusunuri (Shankar)
Ejecutivos de Ocugen Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+117.00%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+153362.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
209.10K
+207300.00%
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
--
--
Ms. Tiffany Hamilton
Ms. Tiffany Hamilton
Head of Communications
Head of Communications
--
--
Dr. Huma Qamar, M.D.
Dr. Huma Qamar, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+117.00%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+153362.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
209.10K
+207300.00%
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2021
FY2020
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.75M
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 18 de ene
Actualizado: dom., 18 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
6.10%
The Vanguard Group, Inc.
5.02%
UBS Financial Services, Inc.
1.43%
Musunuri (Shankar Ph.D)
1.36%
Millennium Management LLC
1.27%
Otro
84.82%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
6.10%
The Vanguard Group, Inc.
5.02%
UBS Financial Services, Inc.
1.43%
Musunuri (Shankar Ph.D)
1.36%
Millennium Management LLC
1.27%
Otro
84.82%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
9.45%
Investment Advisor/Hedge Fund
8.28%
Hedge Fund
3.73%
Individual Investor
2.09%
Research Firm
0.47%
Corporation
0.35%
Venture Capital
0.14%
Bank and Trust
0.05%
Otro
75.44%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
260
72.72M
22.18%
+8.84M
2025Q3
255
51.36M
16.44%
-32.04M
2025Q2
268
78.45M
26.84%
-13.23M
2025Q1
278
81.07M
27.89%
-11.63M
2024Q4
292
76.62M
26.34%
-21.25M
2024Q3
306
84.66M
29.43%
-6.14M
2024Q2
300
72.04M
27.84%
+19.28M
2024Q1
302
36.88M
14.47%
-15.26M
2023Q4
300
30.54M
12.06%
-31.79M
2023Q3
314
37.28M
14.69%
-34.75M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
20.00M
6.4%
+19.70M
+6514.39%
Nov 28, 2025
The Vanguard Group, Inc.
15.22M
4.87%
+450.90K
+3.05%
Sep 30, 2025
UBS Financial Services, Inc.
841.04K
0.27%
+438.31K
+108.83%
Sep 30, 2025
Musunuri (Shankar Ph.D)
1.34M
0.46%
+607.32K
+82.50%
Apr 14, 2025
Millennium Management LLC
4.16M
1.33%
-896.78K
-17.73%
Sep 30, 2025
GMT Capital Corp.
4.15M
1.33%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.83M
1.23%
-1.36M
-26.19%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.68M
1.18%
+189.39K
+5.43%
Sep 30, 2025
Citadel Advisors LLC
1.57M
0.5%
+966.20K
+160.49%
Sep 30, 2025
State Street Investment Management (US)
1.36M
0.43%
+16.46K
+1.23%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.82%
Pacer WealthShield ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.82%
Pacer WealthShield ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
